A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: Relation to motor and cellular parameters of nigrostriatal function

Neurobiology of Disease

Volumn 16, Issue 1, 2004, Pages 110-123

  Lundblad, M ^a   Picconi, B ^a,b   Lindgren, H ^a   Cenci, M A ^a  

^a LUND UNIVERSITY   (Sweden)

^b IRCCS   (Italy)

Author keywords

6 hydroxydopamine; 6 OHDA; caudate putamen; Cellular parameter; CPU; DA; dopamine; L DOPA; medial forebrain bundle; MFB; Nigrostriatal function; Parkinson's disease; PD; PDyn; prodynorphin

Indexed keywords

LEVODOPA; MESSENGER RNA; MOLECULAR MARKER; OXIDOPAMINE; PRODYNORPHIN; PROTEIN FOS;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DYSKINESIA; FORELIMB; LOW DRUG DOSE; MALE; MEDIAL FOREBRAIN BUNDLE; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; SENSORIMOTOR CORTEX; SKELETAL MUSCLE; STATISTICAL SIGNIFICANCE;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; MAZINDOL; MICE; MICE, INBRED C57BL; MOTOR SKILLS; OXIDOPAMINE; PROTEIN BINDING; SUBSTANTIA NIGRA;

EID: 2342459797     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2004.01.007     Document Type: Article

References (35)

1. Akerud P., Canals J.M., Snyder E.Y., Arenas E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J. Neurosci. 21:2001;8108-8118. (Oct. 15)
2. Andersson M., Hilbertson A., Cenci M.A., Lee C.S., Björklund A. Striatal fosB expression is causally linked with L-DOPA induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6:1999;461-474
3. Andersson M., Konradi C., Cenci M.A. cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J. Neurosci. 21(24):2001;9930-9943
4. Andersson M., Westin J.E., Cenci M.A. Time course of striatal ΔFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. Eur. J. Neurosci. 17:2003;1-6
5. Blanchet P.J., Allard P., Gregoire L., Tardif F., Bedard P.J. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can. J. Neurol. Sci. 23:1996;189-193. (Aug.)
6. Bradley A. Mining the mouse genome. Nature. 420:2002;512-514
7. Brotchie J.M., Henry B., Hille C.J., Crossman A.R. Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. DeLong M.R. Advances in Neurology, Dystonia 3. vol. 78:1998;41-52 Lippincott-Raven Publishers, Philadelphia, PA
8. Cenci M.A., Lee C.S., Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10:1998;2694-2706
9. Cenci M.A., Whishaw I.Q., Schallert T. Animal models of neurological deficits: how relevant is the rat? Nat. Rev., Neurosci. 3:2002;574-579
10. Chase T.N. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology. 50:1998;17-25. (May)
11. Civelli O.E., Douglas J., Godstein A., Herbert E. Sequence and expression of the rat prodynorphin gene. Proc. Natl. Acad. Sci. U. S. A. 82:1985;4291-4295
12. Cunningham L.A., Su C. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Exp. Neurol. 174:2002;230-242. (Apr.)
13. Dickson P.R., Lang C.G., Hinton S.C., Kelley A.E. Oral stereotypy induced by amphetamine microinjection into striatum: an anatomical mapping study. Neuroscience. 61:1994;81-91
14. Doucet J.P., Nakabeppu Y., Bedard P.J., Hope B.T., Nestler E.J., Jasmin B.J., Chen J.S.L., Ladarola M.J., St-Jean M., Wigle N., Blanchet P., Grondin R., Robertson G.S. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of ΔfosB-like protein(s) in both the rodent and primate striatum. Eur. J. Neurosci. 8:1996;365-381
15. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 47:2000;S2-S9. (discussion S9-11)
16. Fredduzzi S., Moratalla R., Monopoli A., Cuellar B., Xu K., Ongini E., Impagnatiello F., Schwarzschild M.A., Chen J.F. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J. Neurosci. 22:2002;1054-1062
17. Gainetdinov R.R., Mohn A.R., Caron M.G. Genetic animal models: focus on schizophrenia. Trends Neurosci. 24:2001;527-533
18. Henry B., Crossman A.R., Brotchie J.M. Characterization of enhanced behavioural responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151:1998;334-342
19. Kirik D., Rosenblad C., Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152:1998;259-277
20. Kish S.J., Shannak K., Hornykiewitcz O. Uneven pattern of dopamine loss in the striatum in patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318:1988;876-880
21. Kostic V.S., Marinkovic J., Svetel M., Stefanova E., Przedborski S. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. Eur. J. Neurol. 9:2002;9-14. (Jan.)
22. Lee C.S., Cenci M.A., Schulzer M., Björklund M. Embryonic ventral mesencephalic grafts improve L-DOPA induced dyskinesia in a rat model of Parkinson's disease. Brain. 123:2000;1365-1379
23. Lindner M.D., Plone M.A., Francis J.M., Emerich D.F. Validation of a rodent model of Parkinson's disease: evidence of a therapeutic window for oral Sinemet. Brain Res. Bull. 39:1996;367-372
24. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15:2002;120-132
25. Morrish P.K., Sawle G.V., Brooks D.J. Clinical and [18F] dopa PET findings in early Parkinson's disease. J. Neurol., Neurosurg. Psychiatry. 59:1995;597-600
26. Obeso J.A., Olanow C.W., Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23:2000;S2-S7
27. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates. 2001;Academic Press, San Diego
28. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci. 6:2003;501-506
29. Schallert T., Tillerson J.L. Intervention strategies for degeneration of dopamine neurons in parkinsonism; optimizing behavioural assessment of outcome. Emrich D.F., Dean R.L. III, Sandberg P.R. Central Nervous System Diseases: Innovative Animal Models From Lab to Clinic. 2000;131-151 Human Press, Totova, NJ
30. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 2001;109-125
31. Steiner H., Kitai S.T. Unilateral striatal dopamine depletion: time-dependent effects on cortical function and behavioural correlates. Eur. J. Neurosci. 14:2001;1390-1404
32. Tarantino L.M., Bucan M. Dissection of behavior and psychiatric disorders using the mouse as a model. Hum. Mol. Genet. 9:2000;953-965
33. Tel B.C., Zeng B.Y., Cannizzaro C., Pearce R.K., Rose S., Jenner P. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience. 115:2002;1047-1058
34. Whishaw I.Q., Metz G.A., Kolb B., Pellis S.M. Accelerated nervous system development contributes to behavioral efficiency in the laboratory mouse: a behavioral review and theoretical proposal. Dev. Psychobiol. 2001;151-170
35. Winkler C., Kirik D., Björklund A., Cenci M.A. L-DOPA induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10:2002;165-186